Changes of high mobility protein B1 and soluble advanced glycation end product receptor in heart failure

Heart failure is considered to be a chronic inflammatory disease. High mobility group protein B1(HMGB1) is a sensitive marker of the body's nonspecific inflammation. Extracellular HMGB1 through its high affinity combined with receptor advanced glycation end product receptor(RAGE) participates in the occurrence of cardiovascular disease development. sRAGE can competitively inhibit RAGE biological effect and competitively combine with HMGB1 to reduce and inhibit inflammation, thus delaying the occurrence and development of heart failure. This article summarizes the recent progress in the role of HMGB1 and sRAGE in the development and treatment of cardiovascular disease.